University of Michigan Comprehensive Cancer Center
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Email Address: Cancer-Center-Webmaster@med.umich.edu
The University of Michigan Comprehensive Cancer Center (UMCCC) is part of the University of Michigan Health System and it is a National Cancer Institute-designated Comprehensive Cancer Center. The University of Michigan Comprehensive Cancer Center (UMCC) is one of 21 Comprehensive Cancer Centers participating in the National Comprehensive Cancer Center Network (NCCN). The NCCN’s goal is to ensure the continuous quality of advances in the field of cancer care through uniform, state-of-the-art treatment guidelines.
While the University of Michigan Comprehensive Cancer Center was established in 1987, the Cancer Center Building celebrated its 10-year anniversary in May 2007. Currently, the Cancer Center Building is a nine-story outpatient care and research laboratory facility located adjacent to University of Michigan Hospital, which houses 150 cancer physicians from eight departments, multidisciplinary clinics (62 exam rooms, six consultation, seven procedure/treatment rooms), urgent care services, private long-term infusion areas, treatment rooms for minor surgery, play areas for pediatric patients, and research laboratories, to name a few.
UMCCC’s goal is to offer comprehensive diagnostic, treatment and support services to patients with all types of cancer, including mesothelioma, in an environment that reflects the center’s mission, “the conquest of cancer through innovation and collaboration.”
Co-directed by Dr. Mark B. Orringer and Dr. Gregory P. Kalemkerian, the Thoracic Oncology Program (TOP) focuses on the treatment of patients with intrathoracic cancers including mesothelioma, esophageal cancer, and small cell and non-small cell lung cancer, as well as thymic malignancies. Pioneered by Dr. Mark B. Orringer, transhiatal esophagectomy without thoracotomy has been performed on 2,000 patients at UMCCC over the past 30 years, giving physicians at UMCCC more experience in this procedure than all other physicians (performing the procedure) across the United States. Additionally, TOP is a leader in the development of combined modality therapy in patients treated with surgery, chemotherapy, and radiotherapy, which give patients with esophageal cancer a better chance of survival.
Staffed by thoracic surgeons, medical and radiation oncologists, pulmonologists, gastroenterologists, radiologists, pathologists and nurses, the Thoracic Oncology Program also offers a wide variety of clinical trials, such as chemoprevention studies and the evaluation of state-of-the-art investigational therapies. The Thoracic Oncology Program’s staff members have extensive experience in the area’s of emerging technologies such as esophageal and airway stenting, photodynamic therapy, stereotactic radiosurgery, radiofrequency abalation, ultrasound-guided transbronchial and transesophageal biopsy, and video-assisted thoracoscopy (VAT), which allows for less invasive options in the diagnosis and treatment of patients with thoracic cancers.